Reporting genomic secondary findings: ACMG members weigh in. Read more about Reporting genomic secondary findings: ACMG members weigh in.
Delivery of clinical genetic consultative services in the Veterans Health Administration. Read more about Delivery of clinical genetic consultative services in the Veterans Health Administration.
The economic value of personalized medicine tests: what we know and what we need to know. Read more about The economic value of personalized medicine tests: what we know and what we need to know.
Factors influencing organizational adoption and implementation of clinical genetic services. Read more about Factors influencing organizational adoption and implementation of clinical genetic services.
A cancer genetics toolkit improves access to genetic services through documentation and use of the family history by primary-care clinicians. Read more about A cancer genetics toolkit improves access to genetic services through documentation and use of the family history by primary-care clinicians.
Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency. Read more about Population-based estimates of the prevalence of FMR1 expansion mutations in women with early menopause and primary ovarian insufficiency.
Effective communication of molecular genetic test results to primary care providers. Read more about Effective communication of molecular genetic test results to primary care providers.
Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Read more about Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling.
Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting. Read more about Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.
Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance. Read more about Autoimmune lymphoproliferative syndrome due to FAS mutations outside the signal-transducing death domain: molecular mechanisms and clinical penetrance.
